# ClinicalTrials.gov record NCT04578496

> PeptideScanner retained ClinicalTrials.gov record NCT04578496 at 2026-07-30T20:20:00.372Z. Its registry update date was 2020-11-19, and PeptideScanner's reviewed identity mapping was afamelanotide.

- Evidence object: `story:clinicaltrials-gov-nct04578496-afamelanotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04578496-afamelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04578496-afamelanotide-v1.json
- Content SHA-256: `e3222bce44a7d74d548cb40d0122b41badc7fe931f8986dfb99d7d3f6780ea64`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04578496 ([`ctg-observation-nct04578496-2020-11-19-3e5c750c5850`](#source-ctg-observation-nct04578496-2020-11-19-3e5c750c5850))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04578496 at 2026-07-30T20:20:00.372Z. Its registry update date was 2020-11-19, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct04578496-2020-11-19-3e5c750c5850`](#source-ctg-observation-nct04578496-2020-11-19-3e5c750c5850))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04578496 at 2026-07-30T20:20:00.372Z. Its registry update date was 2020-11-19, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct04578496-2020-11-19-3e5c750c5850`](#source-ctg-observation-nct04578496-2020-11-19-3e5c750c5850))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04578496-2020-11-19-3e5c750c5850`](#source-ctg-observation-nct04578496-2020-11-19-3e5c750c5850))

## Sources

<a id="source-ctg-observation-nct04578496-2020-11-19-3e5c750c5850"></a>
- **ClinicalTrials.gov record NCT04578496 · retained source version 2020-11-19:3e5c750c5850ef2bb240a8134e7d3fbc95ca66c6534219a8d97c29afd25a03bc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04578496) (`ctg-observation-nct04578496-2020-11-19-3e5c750c5850`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04578496." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04578496-afamelanotide-v1.json SHA-256: e3222bce44a7d74d548cb40d0122b41badc7fe931f8986dfb99d7d3f6780ea64.